Tirzepatide vs Semaglutide: Full Comparison for Weight Loss and Diabetes

Summary: In the SURMOUNT-5 head-to-head trial, tirzepatide produced 20.2% weight loss versus 13.7% with semaglutide; tirzepatide also wins on A1C reduction, while semaglutide leads on cardiovascular outcomes, oral availability, and out-of-pocket cost.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

The short answer: in the SURMOUNT-5 head-to-head trial published in 2025, tirzepatide produced 20.2% average weight loss compared with 13.7% for semaglutide over 72 weeks ^[1]. Tirzepatide wins on weight loss and A1C reduction. Semaglutide wins on cardiovascular outcomes data, oral availability, MASH liver disease approval, and cash price. Both share the same gut-related side effect profile, the same boxed warning for thyroid C-cell tumors, and the same once-weekly injection routine.

If your only goal is the largest number on the scale, the data points to tirzepatide. If you want a pill, want the lowest monthly bill, have established heart disease, or have MASH, semaglutide has features tirzepatide does not.

The mechanism difference that drives everything else

Semaglutide is a GLP-1 receptor agonist. It mimics one gut hormone, glucagon-like peptide-1, which slows gastric emptying, increases insulin release in response to food, suppresses glucagon, and signals satiety in the brain.

Tirzepatide is a dual GIP and GLP-1 receptor agonist. It hits the GLP-1 receptor and also activates the receptor for glucose-dependent insulinotropic polypeptide, a second incretin hormone. GIP appears to amplify insulin secretion, increase energy expenditure, and modulate fat storage in ways GLP-1 alone does not ^[5].

That second receptor is the entire reason tirzepatide outperforms semaglutide on weight and A1C in head-to-head trials. Whether the GIP component is doing the heavy lifting through metabolism, appetite suppression, or both is still an active research question. The clinical result is settled.

Head-to-head weight loss: SURMOUNT-5

SURMOUNT-5 is the only randomized head-to-head trial of tirzepatide against semaglutide in adults with obesity and without type 2 diabetes. It enrolled 751 participants, randomized them to maximum tolerated doses of tirzepatide (10 mg or 15 mg) or semaglutide (1.7 mg or 2.4 mg, the full Wegovy maintenance range), and followed them for 72 weeks ^[1].

The gap is 6.5 percentage points of body weight in favor of tirzepatide. For a 230-pound starting weight, that is roughly 15 pounds of additional loss over 72 weeks. Discontinuations from adverse events were slightly lower with tirzepatide, which is the opposite of what most people expect given the higher GI burden tirzepatide carries at the top dose.

Cross-trial weight loss: SURMOUNT-1 vs STEP-1

Before SURMOUNT-5 existed, the field compared tirzepatide and semaglutide indirectly through their pivotal weight loss trials.

STEP-1 tested semaglutide 2.4 mg weekly in 1,961 adults with obesity or overweight and at least one weight-related comorbidity, over 68 weeks. Mean weight change was -14.9% for semaglutide versus -2.4% for placebo ^[3]. About one-third of treated participants lost at least 20% of body weight.

SURMOUNT-1 tested tirzepatide 5 mg, 10 mg, and 15 mg in 2,539 adults with obesity over 72 weeks. Mean weight change at the 15 mg dose was -20.9% in the modified intention-to-treat analysis (and as high as -22.5% in the on-treatment analysis), versus -3.1% for placebo ^[2]. The 5 mg dose alone matched semaglutide's top-line number at roughly 15%.

These trials used different populations and slightly different protocols, so the comparison is suggestive rather than definitive. SURMOUNT-5 confirmed what the cross-trial numbers implied: tirzepatide produces larger average weight loss than semaglutide at maximum tolerated doses.

A1C reduction in type 2 diabetes: SURPASS-2

For type 2 diabetes, the head-to-head data is older and just as clear. SURPASS-2 randomized 1,879 adults with type 2 diabetes inadequately controlled on metformin to tirzepatide (5, 10, or 15 mg) or semaglutide 1 mg weekly. Treatment ran for 40 weeks ^[4].

Tirzepatide outperformed semaglutide at every dose on both A1C and weight. The 15 mg tirzepatide arm hit A1C below 5.7%, the non-diabetic range, in 46% of participants. Semaglutide hit that threshold in 19%.

The fair caveat: SURPASS-2 compared tirzepatide against semaglutide 1 mg, not the higher 2 mg dose that the FDA approved for type 2 diabetes in March 2022 ^[5]. Semaglutide 2 mg likely narrows the gap, but it has not been studied head-to-head against tirzepatide in a published phase 3 trial.

A 22-study meta-analysis covering more than 18,000 participants ranked tirzepatide 15 mg first for A1C reduction (mean difference 2.0% vs placebo), tirzepatide 10 mg second (1.86%), and semaglutide 2 mg third (1.62%) ^[5]. Tirzepatide doses of 5 mg also beat semaglutide 0.5 and 1 mg.

Side effects: similar profile, dose-dependent intensity

Both drugs share the same dominant side effect profile: gastrointestinal, dose-dependent, worst during titration, and usually improving with time at a stable dose.

The shared list:

• Nausea
• Vomiting
• Diarrhea
• Constipation
• Abdominal pain and bloating
• Reduced appetite and early satiety
• Fatigue, especially in the first weeks
• Injection site reactions
• Acid reflux

In SURMOUNT-5, GI side effects were common in both arms. Vomiting occurred more often with semaglutide. Injection site reactions occurred slightly more often with tirzepatide. Treatment discontinuations for adverse events were 6.1% on tirzepatide versus 8.0% on semaglutide ^[1].

Serious side effects shared by both

The boxed warning is identical: a theoretical risk of medullary thyroid carcinoma based on rat studies. Do not use either drug if you or a first-degree relative has medullary thyroid carcinoma or multiple endocrine neoplasia type 2 ^[5].

Other shared serious risks:

• Acute pancreatitis. Stop the drug and see a clinician for severe persistent abdominal pain.
• Gallbladder disease, including gallstones and cholecystitis. Rapid weight loss increases this risk.
• Acute kidney injury, usually mediated by dehydration from vomiting and diarrhea.
• Ileus (intestinal blockage), a low-frequency post-marketing signal added to both labels.
• Aspiration risk under anesthesia, due to delayed gastric emptying. Tell your surgical team you are on a GLP-1 before any procedure.
• Diabetic retinopathy worsening in people with type 2 diabetes (better documented for semaglutide but on both labels).

Muscle preservation and lean mass

Both drugs cause some lean body mass loss alongside fat loss, which is normal for any meaningful weight loss intervention. Some observational data suggests tirzepatide may produce slightly higher lean mass loss than semaglutide at equivalent weight loss, though the comparison is confounded by the larger absolute weight loss tirzepatide produces. The clinically actionable advice is the same regardless of which drug you pick: resistance train two to three times a week and target 1.2 to 1.6 grams of protein per kilogram of body weight per day during the weight loss phase.

Cost comparison

Both drugs are expensive. Direct-to-consumer cash pricing through manufacturer savings programs sits in a similar range, but the cheapest semaglutide options beat the cheapest tirzepatide options.

These numbers are direct-from-manufacturer cash programs, which require no insurance and ship from the brand. Insured pricing varies wildly. If your plan covers either drug at a reasonable copay, take that copay over any cash program. Compounded tirzepatide and semaglutide also exist in the cash market, often below brand list prices, though the FDA's 2024 ruling that tirzepatide is no longer in shortage narrowed the legal scope of compounding for that specific drug.

Availability and brand names

Semaglutide is sold under four brand names in the US:

• Ozempic: weekly injection, FDA approved for type 2 diabetes and cardiovascular risk reduction in T2D and CKD.
• Wegovy injection: weekly injection, FDA approved for chronic weight management, cardiovascular risk reduction in adults with established heart disease, and MASH liver disease.
• Wegovy HD: weekly injection, 7.2 mg, FDA approved as a step-up after the 2.4 mg dose has been tolerated for 4 weeks.
• Wegovy oral tablet (formerly Rybelsus indication expansion): daily pill for weight management.
• Rybelsus: daily oral pill, FDA approved for type 2 diabetes.

Tirzepatide is sold under two brand names:

• Mounjaro: weekly injection, FDA approved for type 2 diabetes.
• Zepbound: weekly injection, FDA approved for chronic weight management and moderate to severe obstructive sleep apnea in adults with obesity. A daily oral tirzepatide is expected to launch later in 2026.

The oral-versus-injection split is the practical difference for many patients. As of mid-2026, the only FDA-approved oral GLP-1 medications are semaglutide forms (Rybelsus and the Wegovy oral tablet). If you cannot or will not inject, that narrows the choice to semaglutide.

Insurance coverage differences

Insurance behaves very differently for each indication:

• Type 2 diabetes: most commercial plans and Medicare cover both Ozempic and Mounjaro, often with a prior authorization. Tier placement varies.
• Obesity without diabetes: coverage is uneven. Medicare does not cover weight loss medications under its standard drug benefit. Many commercial plans either exclude weight loss medications or require demonstrated BMI, prior diet program participation, and step therapy. Wegovy and Zepbound have similar coverage profiles, but specific formulary placement differs plan by plan.
• Cardiovascular risk reduction: Wegovy gained an FDA indication to reduce major adverse cardiovascular events in adults with obesity and established heart disease. Some Medicare Part D plans cover it for that indication. Tirzepatide does not yet have this approval. The SURPASS-CVOT cardiovascular outcomes trial for tirzepatide is ongoing.
• MASH (liver disease): Wegovy has accelerated approval. Tirzepatide does not.
• Obstructive sleep apnea: Zepbound has an FDA indication. Wegovy does not.

The indication you qualify under often determines whether you get coverage at all. A patient with obesity and OSA may get Zepbound covered while the same patient could not get Wegovy covered. A patient with obesity and established heart disease may get Wegovy covered while Zepbound is denied.

Dosage chart

Both drugs use a slow, deliberate titration schedule designed around GI tolerability. The starting doses are below therapeutic; the maintenance doses are where weight loss and A1C effects come from.

Tirzepatide has six dose strengths (counting the 2.5 mg initiation), which gives more room to find a dose where side effects are manageable. Semaglutide has fewer steps, which means fewer chances to land on a side-effect-friendly stopping point if 2.4 mg is too much.

Who tirzepatide is better for

Pick tirzepatide if your goal aligns with any of the following:

• Maximum weight loss is the top priority. SURMOUNT-5 settled this; tirzepatide produces about 6 to 7 percentage points more weight loss than semaglutide ^[1].
• Type 2 diabetes with high A1C. SURPASS-2 and the broader meta-analysis put tirzepatide ahead on A1C reduction at every dose pair ^[4][5].
• Obstructive sleep apnea with obesity. Zepbound has the FDA indication; Wegovy does not.
• You tolerate injections fine and have access to either Mounjaro/Zepbound or a covered tirzepatide product.
• You experienced inadequate weight loss on semaglutide. Real-world switching from semaglutide to tirzepatide is common and frequently produces additional weight loss.

Who semaglutide is better for

Pick semaglutide if your situation includes any of the following:

• You want a pill. Rybelsus and the Wegovy oral tablet are the only FDA-approved oral GLP-1 options. Tirzepatide is injection-only until the oral version launches.
• You have established cardiovascular disease. Wegovy is approved to reduce major adverse cardiovascular events in adults with obesity and heart disease. Tirzepatide does not yet have this indication.
• You have MASH (metabolic dysfunction-associated steatohepatitis). Wegovy has accelerated approval for MASH. Tirzepatide does not.
• You are paying cash and price is the deciding factor. Wegovy oral at $199 to $299 and Wegovy injection at $349 sit below Zepbound and Mounjaro at $499 list.
• You are an adolescent. Wegovy is approved from age 12 for obesity. Zepbound is not currently approved in adolescents. (Mounjaro is approved from age 10 for type 2 diabetes, so for adolescent diabetes the picture flips.)
• You had intolerable side effects on tirzepatide. In SURMOUNT-5, tirzepatide had fewer total discontinuations, but individual response varies. People who could not tolerate tirzepatide sometimes do well on semaglutide.

Recommendation matrix

Switching from semaglutide to tirzepatide

Switching is common and generally safe under prescriber supervision. There is no required washout period since both drugs work through the same general pathway. The standard approach: stop semaglutide on a Sunday, start tirzepatide 2.5 mg the following Sunday. Most clinicians restart titration from the bottom rather than dose-matching, because tirzepatide's GI side effects are dose-dependent and starting low protects against a rough first month. Some prescribers will start at 5 mg in patients who were tolerating semaglutide 2.4 mg comfortably. Discuss the plan before you stop the first drug.

The reverse switch, tirzepatide to semaglutide, is less common and usually driven by insurance changes, cost, or wanting an oral option. Same principle: restart titration from the bottom unless your prescriber tells you otherwise.

Fatty liver, insulin resistance, and other indications

Semaglutide has FDA accelerated approval for MASH, the fibrosing inflammatory form of non-alcoholic fatty liver disease. The approval came from the ESSENCE trial, which showed reduced fibrosis and resolution of steatohepatitis at 72 weeks. Tirzepatide has positive phase 2 data in MASH (SYNERGY-NASH showed up to 73% resolution of steatohepatitis at 52 weeks at the 15 mg dose) but is not yet FDA approved for the indication.

For insulin resistance more broadly, both drugs improve fasting insulin, HOMA-IR, and triglyceride levels in obese and diabetic populations. Tirzepatide's GIP component appears to have additional effects on adipose tissue insulin sensitivity, but the practical implication is the same: either drug, combined with weight loss, will improve insulin resistance in most patients.

For joint pain, neither drug directly treats arthritis, but weight loss of the magnitude both produce reliably reduces mechanical knee and hip joint loading. SELECT and STEP HFpEF data on semaglutide and SUMMIT data on tirzepatide both showed quality-of-life and functional improvements that included less reported joint pain.

Real-world results outside of trials

Clinical trial results assume strict adherence, study-team-monitored titration, and a motivated population. Real-world weight loss is typically lower than trial averages, both for semaglutide and tirzepatide. Retrospective studies of US electronic health records have reported one-year mean weight loss in the range of 8% to 12% for tirzepatide and 5% to 7% for semaglutide, with high variability. The relative gap (tirzepatide ahead by roughly 3 to 5 percentage points) tracks what the head-to-head trial shows.

The two largest reasons real-world numbers fall short of trial numbers: people stop the drug for cost or side effects long before 72 weeks, and people titrate slowly or cap below the maximum dose. Both factors hit semaglutide and tirzepatide similarly.

2026 landscape

A few moving pieces matter for anyone making a decision in 2026:

• Oral tirzepatide is expected to launch later in 2026, which will erase semaglutide's pill monopoly.
• Wegovy HD (7.2 mg) is now widely available and produces weight loss in the low 20s range, narrowing tirzepatide's advantage at the absolute top of the dose curve.
• Cardiovascular outcomes for tirzepatide (SURPASS-CVOT) are expected to read out in late 2026 or 2027. If positive, the heart disease indication gap with semaglutide closes.
• MASH trials for tirzepatide (SYNERGY-NASH phase 3) are ongoing.
• Cash prices continue to fall slowly across both drugs as direct-to-consumer programs compete.

The fundamental tradeoff is unlikely to change in the next 12 months: tirzepatide leads on weight and A1C, semaglutide leads on cardiovascular and liver indications, and both share the same side effect and safety profile.

Frequently asked questions

Is tirzepatide better than semaglutide for weight loss?

In SURMOUNT-5, the head-to-head trial published in 2025, tirzepatide produced 20.2% mean weight loss versus 13.7% for semaglutide over 72 weeks. Tirzepatide produces larger average weight loss in adults with obesity.

What is the difference between Ozempic, Wegovy, Mounjaro, and Zepbound?

Ozempic and Wegovy are both semaglutide; Ozempic is approved for type 2 diabetes and Wegovy for weight loss. Mounjaro and Zepbound are both tirzepatide; Mounjaro is approved for diabetes and Zepbound for weight loss and sleep apnea.

How do tirzepatide and semaglutide compare for type 2 diabetes?

In SURPASS-2, tirzepatide reduced A1C more than semaglutide 1 mg at every dose tested (2.01% to 2.30% vs 1.86%), and produced more weight loss. Tirzepatide is generally more effective for diabetes glycemic control.

Are the side effects of semaglutide and tirzepatide the same?

The side effect profiles are very similar: nausea, vomiting, diarrhea, constipation, fatigue, and injection site reactions. In SURMOUNT-5, vomiting was slightly more common with semaglutide and injection site reactions slightly more common with tirzepatide.

Which is cheaper, semaglutide or tirzepatide?

Direct-to-consumer cash prices in 2026: Wegovy oral $199 to $299/month, Wegovy injection $349/month, Ozempic $349 to $499/month, Mounjaro and Zepbound $499/month. Semaglutide options sit below tirzepatide on cash pricing.

Can I switch from semaglutide to tirzepatide?

Yes, under prescriber supervision. The standard approach is to stop semaglutide and start tirzepatide 2.5 mg the following week, then titrate up. Most clinicians restart titration from the bottom rather than dose-match.

Is there an oral version of tirzepatide?

Not yet as of mid-2026. Tirzepatide is injection-only in the US through Mounjaro and Zepbound. An oral tirzepatide is expected to launch later in 2026. Semaglutide is available as a daily pill (Rybelsus and Wegovy oral tablet).

Does semaglutide or tirzepatide preserve more muscle?

Both produce some lean body mass loss alongside fat loss, which is normal during meaningful weight loss. Tirzepatide may produce slightly higher absolute lean mass loss because it produces more total weight loss. Resistance training and adequate protein intake matter more than which drug you pick.

Which is better for fatty liver disease?

Semaglutide (Wegovy) has FDA accelerated approval for MASH liver disease. Tirzepatide has positive phase 2 data (SYNERGY-NASH) but no FDA approval yet for MASH. For documented MASH, semaglutide is currently the on-label option.

Does tirzepatide reduce belly fat more than semaglutide?

Both drugs reduce visceral and subcutaneous abdominal fat in proportion to overall weight loss. Tirzepatide produces more total weight loss, so most people see more abdominal fat loss with tirzepatide. Body composition imaging studies show similar proportional fat distribution changes.

Which is better for insulin resistance?

Both improve fasting insulin, HOMA-IR, and triglycerides. Tirzepatide tends to produce larger improvements at maximum doses, driven both by greater weight loss and by GIP receptor effects on adipose tissue insulin sensitivity.

Does tirzepatide or semaglutide cause more fatigue?

Fatigue in the first weeks is common for both, driven primarily by the steep drop in calorie intake during titration. Neither drug is clearly worse for energy at maintenance doses. Adequate protein, hydration, and electrolytes resolve most cases.

What this article does not cover

This page is the head-to-head comparison. Specific dosing math, individual side effect management, switching protocols, brand-specific cost programs, and the dedicated comparisons of Mounjaro vs Ozempic, Zepbound vs Wegovy, and Rybelsus vs Mounjaro each have their own pages on this site. Use the search to find them. The data here covers the trials, the mechanism difference, and the indication-by-indication choice. Everything else is operational detail you can layer on once you and your prescriber have picked a drug.